The psoriasis-eczema overlap phenotype, and why JAK1 inhibition works where biologics did not

Design

two-centre prospective observational study with immunological profiling of lesional skin and blood, comparison against typical psoriasis and atopic dermatitis cohorts

Population

30 adults with psoriasis-atopic dermatitis overlapping phenotype, aged 13 to 72, mean age 49.7

Primary outcome

clinicopathological and immunological characterisation, and response to prior biologics versus JAK1 inhibition

Effect

inadequate responses to psoriasis-targeted (n=18) and AD-targeted (n=15) biologics; JAK1 inhibitors achieved minimal disease activity (BSA <=2%, NRS <=1) over median 17 months

This two-centre prospective study characterised 30 adults, aged 13 to 72 with a mean age of 49.7, whose disease showed overlapping psoriatic and eczematous histology, and compared them against typical psoriasis and atopic dermatitis cohorts. Clinically they presented with ill-defined erythematous plaques carrying thin scales, excoriation and intense itch.

The immunology explains the therapeutic problem. Both type 2 (Th2/Tc2) and type 3 (Th17/Tc17) programmes were active simultaneously in lesional skin and in blood, with JAK1-STAT2/6 signalling involved. That is why targeted biologics disappointed: 18 patients had received psoriasis-targeted biologics and 15 atopic dermatitis-targeted biologics, with often inadequate responses, because each drug blocks one axis while the other continues. JAK1 inhibitors, acting downstream of both, achieved minimal disease activity — body surface area 2% or less and itch numerical rating scale 1 or less — over a median 17 months of follow-up. No patient converted to a classic psoriasis or atopic dermatitis phenotype, supporting this being a stable entity rather than a transitional state.

The evidence grade needs saying plainly: 30 patients, no control arm for the JAK1 treatment, and immunological work done in a subset. This is a phenotype description with an uncontrolled treatment observation attached, not a trial. What it justifies is a change in reasoning rather than an automatic prescription — when a patient has mixed features and has already failed a biologic aimed at one axis, the next step is not a different biologic aimed at the same axis, and a JAK1 inhibitor is a rational choice with its own class risks to weigh and consent for.

• Suspect the overlap phenotype in adults with mixed histology, thin scale and intense itch failing targeted biologics
• Do not cycle to a second biologic aimed at the same immune axis after the first has partially failed
• Consider a JAK1 inhibitor, consenting for the class cardiovascular, thromboembolic and malignancy warnings
• Set an objective response target — this series used body surface area 2% or less with itch score 1 or less
• Thirty patients with no control arm: treat as a rational option, not an established standard

The statistics, in plain English

There is no comparative statistic here because the treatment observation was uncontrolled: patients who improved on a JAK1 inhibitor did so after other drugs failed, and regression to the mean plus selection of those who stayed in follow-up both flatter the result. Thirty patients is enough to describe a phenotype consistently and far too few to estimate how often the drug works. The absence of conversion to classic phenotypes over follow-up is the more robust observation, because it is a simple count rather than a treatment effect.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.